Plaque Psoriasis

This study is an open-label study, consisting of a 12-week primary treatment phase and an optional 40-week long-term extension phase in which all eligible subjects will receive tapinarof cream, 1% once daily. At the end of the 12-week primary treatment phase, subjects will have the option to continue for 40 additional weeks of treatment. Subjects who choose not to participate in the optional 40-week long-term extension phase will complete a follow-up visit approximately one week after the end of the primary treatment phase.

To Qualify, you must meet the following INCLUSION CRITERIA:

1.)  2 - 17 years of age

2.)  Have Mild to Moderate Plaque Psoriasis with >3% Body Surface Area Affected 

3.)  Parental consent

To Qualify, you must NOT meet the following EXCLUSION CRITERIA:

1.)  Non-Plaque variant Psoriasis

2.)  Current infection in psoriatic lesions

3.)  Previous use of tapinarof 

 ClinicalTrials.gov Identifier: NCT05172726 

https://www.clinicaltrials.gov/ct2/show/NCT05172726?term=dermavant&cond=Plaque+Psoriasis&cntry=US&state=US%3AWA&city=Spokane&draw=2&rank=2